Bayer agrees to buy Perfuse Therapeutics for up to $2.45 billion
Updated
Updated · Bloomberg · May 6
Bayer agrees to buy Perfuse Therapeutics for up to $2.45 billion
13 articles · Updated · Bloomberg · May 6
The German drugmaker said it will pay $300 million upfront, with further development, regulatory and commercial milestone payments tied to success criteria.
Perfuse makes eye medicines, and the acquisition is aimed at bolstering Bayer's drug pipeline as generic competition increases for some of its blockbuster treatments.
The deal underscores Bayer's push to add new products through acquisitions as it seeks future growth and offsets pressure on established medicines.
Is Bayer's $2.45 billion deal a cure for its patent woes or a costly gamble on a Phase II drug?
As Bayer bets billions on a new drug, can its AI-powered research prevent another blockbuster failure?
After a five-year deal drought, has Bayer found the first real cure for a leading cause of blindness?